ProBioGen has partnered with Polpharma Biologics, an international biotech company, to conduct high-performance cell line development services for Polpharma’s biosimilar candidate.

Leveraging its cell line development platform, CHO.RiGHT, including the proprietary DirectedLuck transposase technology and decades of expertise in cell line development for new biological entities and biosimilars, ProBioGen will generate a robust, high-yielding production cell line that meets the critical quality attribute profile of Polpharma’s biosimilar. This collaboration enhances Polpharma’s capacity to meet increasing demands and accelerate its biosimilar pipeline by ensuring high biosimilar quality, stable cell lines, and fast timelines.

“We are excited to support Polpharma Biologics in bringing their product to the clinic,” said Dr. Volker Sandig, Chief Scientific Officer at ProBioGen. “By applying our extensive expertise in cell line engineering, we provide Polpharma with a best-in-class expression platform that ensures efficiency, expression stability and superior quality.”

Dr. Konstantin Matentzoglu, Supervisory Board Member from Polpharma Biologics, added: “Partnering with a reliable CDMO to support our expanding capacity needs was crucial. ProBioGen’s track record, proven expertise, agility and dedication to high-standard services were key factors in our decision to collaborate. This partnership reflects the increasing demand for biosimilars and reinforces our commitment to improving patient access while reducing healthcare costs by using high-expressing production cell lines.”

ProBioGen remains committed to enabling the rapid and efficient development of biosimilars, aligning with Polpharma Biologics’ mission to provide affordable biologics. Through this and future collaborations, both companies aim to accelerate development timelines and drive the production of next-generation therapies that address high medical needs.